| Literature DB >> 28447377 |
Kabir Sardana1, Shikha Chugh2, Rashmi Ranjan2, Nita Khurana2,3.
Abstract
Lupus miliaris disseminatus faciei (LMDF) is a chronic, inflammatory dermatosis of unknown etiology, characterized by multiple, monomorphic, symmetrical, reddish-brown papules over forehead, cheeks, and eyelids. Histopathology shows perifollicular epitheloid cell granuloma. Though numerous therapies, ranging from cyclines, macrolides, dapsone tranilast, isotretinoin, steroids, and tacrolimus have been tried, the results are inconsistent, except with systemic steroids. One approach is to administer therapies based on the histological findings and the corresponding mode of action of drugs, thus antibiotics and dapsone are effective in the early inflammatory stage while clofazamine can be used in the granulomatous stage of the disease. A case of LMDF, recalcitrant to multiple systemic therapies, who responded dramatically to cyclosporine (50 mg twice daily), which probably was due to the specific effect on TH 1 cell response which mediates cell mediated immunity responsible for granulomatous changes on histology has been reported. This case highlights that LMDF is an independent granulomatous entity (not a variant of rosacea or tuberculosis).Entities:
Keywords: cyclosporine; lupus miliaris disseminatus faciei
Mesh:
Substances:
Year: 2017 PMID: 28447377 DOI: 10.1111/dth.12496
Source DB: PubMed Journal: Dermatol Ther ISSN: 1396-0296 Impact factor: 2.851